YKYon Hui Kim

Yon Hui Kim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yon Hui Kim has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Jinhyuk Lee

    Korean Bioinformation Center, Korea Research Institute of Bioscience and Biotechnology , 34141 Daejeon, Korea

    3 shared publications
  • Seungyoon Nam

    Department of Genome Medicine and Science, Gachon Institute of Genome Medicine and Science, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea

    3 shared publications
  • Hyo Jin Eom

    Research and Development Department, Corestem Inc., Gyeonggi-do, 13486, Korea

    2 shared publications
  • Jin-Hee Kim

    College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon, 21983, Korea

    2 shared publications
  • Sungjin Park

    Department of Genome Medicine and Science, College of Medicine, Gachon University , 21565 Incheon, Korea

    2 shared publications
  • Sungjin Park

    Institute of Human Behavior & Genetics, College of Medicine, Korea University, 73 Goryeodae-ro, Seongbuk-gu, Seoul 02841, Republic of Korea

    2 shared publications

Latest Publications

  • Open Access

    Second-Generation JK-206 Targets the Oncogenic Signal Mediator RHOA in Gastric Cancer

    by Myeonghun Beak, Sungjin Park, Jin-Hee Kim, Hyo Jin Eom, Ho-Yeon Lee, Yon Hui Kim, Jinhyuk Lee, Seungyoon Nam

    Ras homologous A (RHOA), a signal mediator and a GTPase, is known to be associated with the progression of gastric cancer (GC), which is the fourth most common cause of death in the world. Previously, we designed pharmacologically optimized inhibitors against RHOA, including JK-136 and JK-139. Based on this previous work, we performed lead optimization and designed novel RHOA inhibitors for greater anti-GC potency. Two of these compounds, JK-206 and JK-312, could successfully inhibit the viability and migration of GC cell lines. Furthermore, using transcriptomic analysis of GC cells treated with JK-206, we revealed that the inhibition of RHOA might be associated with the inhibition of the mitogenic pathway. Therefore, JK-206 treatment for RHOA inhibition may be a new therapeutic strategy for regulating GC proliferation and migration.


  • PATHOME-Drug: a subpathway-based polypharmacology drug-repositioning method

    by Seungyoon Nam, Sungyoung Lee, Sungjin Park, Jinhyuk Lee, Aron Park, Yon Hui Kim, Taesung Park

    Drug repositioning reveals novel indications for existing drugs and in particular, diseases with no available drugs. Diverse computational drug repositioning methods have been proposed by measuring either drug-treated gene expression signatures or the proximity of drug targets and disease proteins found in prior networks. However, these methods do not explain which signaling subparts allow potential drugs to be selected, and do not consider polypharmacology, i.e. multiple targets of a known drug, in specific subparts. Here, to address the limitations, we developed a subpathway-based polypharmacology drug repositioning method, PATHOME-Drug, based on drug-associated transcriptomes. Specifically, this tool locates subparts of signaling cascading related to phenotype changes (e.g. disease status changes), and identifies existing approved drugs such that their multiple targets are enriched in the subparts. We show that our method demonstrated better performance for detecting signaling context and specific drugs/compounds, compared to WebGestalt and clusterProfiler, for both real biological and simulated datasets. We believe that our tool can successfully address the current shortage of targeted therapy agents. The web-service is available at http://statgen.snu.ac.kr/software/pathome. The source codes and data are available at https://github.com/labnams/pathome-drug. Supplementary data are available at Bioinformatics online.


  • Rational design of small molecule RHOA inhibitors for gastric cancer

    by Jin-Hee Kim, Sungjin Park, Seung Mook Lim, Hyo Jin Eom, Curt Balch, Jinhyuk Lee, Gi Jin Kim, Jin-Hyun Jeong, Seungyoon Nam, Yon Hui Kim

    Previously, we identified Ras homologous A (RHOA) as a major signaling hub in gastric cancer (GC), the third most common cause of cancer death in the world, prompting us to rationally design an efficacious inhibitor of this oncogenic GTPase. Here, based on that previous work, we extend those computational analyses to further pharmacologically optimize anti-RHOA hydrazide derivatives for greater anti-GC potency. Two of these, JK-136 and JK-139, potently inhibited cell viability and migration/invasion of GC cell lines, and mouse xenografts, diversely expressing RHOA. Moreover, JK-136′s binding affinity for RHOA was >140-fold greater than Rhosin, a nonclinical RHOA inhibitor. Network analysis of JK-136/-139 vs. Rhosin treatments indicated downregulation of the sphingosine-1-phosphate, as an emerging cancer metabolic pathway in cell migration and motility. We assert that identifying and targeting oncogenic signaling hubs, such as RHOA, represents an emerging strategy for the design, characterization, and translation of new antineoplastics, against gastric and other cancers.


  • Open Access

    Differential effects, on oncogenic pathway signalling, by derivatives of the HNF4 α inhibitor BI6015

    by Jin-Hee Kim, Hyo Jin Eom, GyuTae Lim, Sungjin Park, Jinhyuk Lee, Seungyoon Nam, Yon Hui Kim, Jin-Hyun Jeong

    Background Gastric cancer (GC) is a highly heterogeneous disease with few “targeted” therapeutic options. Previously, we demonstrated involvement of the transcription factor HNF4α in human GC tumours, and the developmental signal mediator, WNT5A, as a prognostic GC biomarker. One previously developed HNF4α antagonist, BI6015, while not advancing beyond preclinical stages, remains useful for studying GC. Methods Here, we characterised the antineoplastic signalling activity of derivatives of BI6015, including transfer of the nitro group from the para position, relative to a methyl group on its benzene ring, to the ortho- and meta positions. We assessed binding efficacy, through surface plasmon resonance and docking studies, while biologic activity was assessed by antimitogenic efficacy against a panel of GC cell lines, and dysregulated transcriptomes, followed by pathway and subpathway analysis. Results The para derivative of BI6105 was found substantially more growth inhibitory, and effective, in downregulating numerous oncogenic signal pathways, including the embryonic cascade WNT. The ortho and meta derivatives, however, failed to downregulate WNT or other embryonic signalling pathways, unable to suppress GC growth. Conclusion Straightforward strategies, employing bioinformatics analyses, to facilitate the effective design and development of “druggable” transcription factor inhibitors, are useful for targeting specific oncogenic signalling pathways, in GC and other cancers.